Soluble receptor for advanced glycation end-products and progression of airway diseaseReportar como inadecuado

Soluble receptor for advanced glycation end-products and progression of airway disease - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Pulmonary Medicine

, 14:68

COPD and occupational lung disease


BackgroundThe receptor for advanced glycation end-products RAGE is highly expressed in the lung, where it is believed to have a homeostatic role. Reduced plasma levels of soluble RAGE sRAGE have been reported in patients with chronic obstructive pulmonary disease COPD. The aim of the present study was to evaluate the association of plasma sRAGE levels with a longitudinal decline of lung function. We have also measured plasma levels of high mobility group box 1 HMGB1, a RAGE ligand which has been associated with chronic inflammatory diseases including COPD.

MethodsBaseline plasma concentrations of sRAGE and HMGB1 were measured in non-smokers n = 32, smokers without COPD n = 212, and smokers with COPD n = 51, and the associations of the plasma sRAGE and HMGB1 levels with longitudinal declines of lung function during a 4-year follow-up period were analysed.

ResultsThe plasma levels of sRAGE were significantly lower in smokers without COPD and in smokers with COPD, as compared to those of non-smokers. Plasma sRAGE levels positively correlated with FVC and FEV1 and inversely correlated with BMI and pack-years. Lower sRAGE levels were associated with greater declines of FEV1-FVC over 4 years in all participants. Moreover, multivariate regression analysis indicated that the baseline plasma sRAGE concentration was an independent predictor of FEV1-FVC decline in all groups. A subgroup analysis showed that decreased sRAGE levels are significantly associated with a more rapid decline of FEV1-FVC in smokers with COPD. There was no significant correlation between plasma HMGB1 levels and longitudinal decline of lung function.

ConclusionsLower plasma concentrations of sRAGE were associated with greater progression of airflow limitations over time, especially in smokers with COPD, suggesting that RAGE might have a protective role in the lung.

AbbreviationsCOPDChronic obstructive pulmonary disease

FEV1Forced expiratory volume in one second

FVCForced vital capacity

HMGB1High mobility group box 1

sRAGESoluble receptor for advanced glycation end-products.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2466-14-68 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Hiroshi Iwamoto - Jing Gao - Ville Pulkkinen - Tuula Toljamo - Pentti Nieminen - Witold Mazur


Documentos relacionados